News
MedPage Today on MSN6d
Semaglutide Gets FDA Greenlight for MASH
The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...
The FDA has granted accelerated approval of Wegovy® (semaglutide) for adults with moderate to advanced metabolic ...
The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...
Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...
The FDA has approved Wegovy for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis ...
The FDA has approved semaglutide for treating MASH, a significant advancement in liver disease management. Semaglutide, ...
Everyday Health on MSN4d
People With Weight-Related Chronic Liver Disease Have a New Treatment Option
The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...
Pharmaceutical Technology on MSN6d
Wegovy becomes first GLP-1RA to gain FDA MASH approval
Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...
Wegovy is the first GLP-1 drug approved to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). An ...
The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated ...
Health and Me on MSN6d
Wegovy Approved For MASH Treatment With Fibrosis But No Cirrhosis
FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback